Skip to main content
Article
Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system.
Obstetrics and gynecology
  • J. Kresowik
  • Ginny L. Ryan, University of Iowa
  • Bradley J. Van Voorhis, University of Iowa
Document Type
Article
Peer Reviewed
1
Publication Date
2-1-2008
Abstract

BACKGROUND: Intrauterine progesterone therapy has been proposed as a potential uterine-sparing treatment for atypical endometrial hyperplasia and adenocarcinoma.

CASE: We present a case of an infertility patient with atypical endometrial hyperplasia who was treated with the levonorgestrel-releasing intrauterine system for 6 months. At follow-up, she was noted to have an increasing endometrial thickness on ultrasonography, and biopsy revealed progression of her lesion to adenocarcinoma.

CONCLUSION: Although there is a need for uterine-sparing treatment for atypical endometrial hyperplasia and early adenocarcinoma, especially in the setting of desired fertility, caution should be exercised. We do not recommend using the levonorgestrel-releasing intrauterine system as a treatment for atypical hyperplasia or adenocarcinoma until further studies demonstrate the efficacy of this treatment.

Keywords
  • Adenocarcinoma,
  • Adult,
  • Contraceptive Agents,
  • Female,
  • Endometrial Hyperplasia,
  • Endometrial Neoplasms,
  • Female,
  • Humans,
  • Intrauterine Devices,
  • Medicated,
  • Levonorgestrel,
  • Treatment Failure
Published Article/Book Citation
Obstetrics and gynecology (2008) 111:2 Pt 2, pp. 547-549.
Citation Information
J. Kresowik, Ginny L. Ryan and Bradley J. Van Voorhis. "Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system." Obstetrics and gynecology Vol. 111 Iss. 2 Pt 2 (2008) p. 547 - 549 ISSN: 0029-7844
Available at: http://works.bepress.com/ginny_ryan/25/